Published by Global Banking & Finance Review®
Posted on June 17, 2025
2 min readLast updated: January 23, 2026
Add as preferred source on GoogleFresenius Medical Care's 2030 targets disappointed investors, causing a 5.6% share drop. The company plans a €1 billion share buyback and aims for a 'mid-teens' operating income margin.
(Reuters) -Fresenius Medical Care, the world's largest dialysis specialist, on Tuesday set targets for the period to 2030 and said that it plans to embark on a 1 billion euro ($1.16 billion) share buyback programme.
However, the plans underwhelmed investors and shares in the company fell by as much as 5.6%, making it the poorest performer within Germany's blue-chip index.
Ahead of its capital markets day, the dialysis provider for 300,000 patients worldwide said it aimed to reach a "mid-teens" percent operating income margin excluding one-off items by 2030.
The company declined to specify how it defined "mid-teens".
For 2025, operating income excluding one-off items is expected to increase by the "high teens to high twenties" percentage range, benefiting from a margin of 11 to 12 percent, the company said.
"FMC has only delivered what was expected - now no further buying triggers (are) to be expected and investors are retreating to the sidelines for the time being," a Germany-based trader told Reuters.
The company is also targeting an additional 300 million euros savings within two years, it said.
"We plan to return excess capital to our shareholders through a 30 to 40% dividend payout plus the opportunity for regular share buybacks," Chief Executive Officer Helen Giza said in a statement.
Fresenius Medical Care said that it is planning 800 million euros to 1 billion euros of capital expenditure each year between 2025 and 2030. It lowered its target band for net financial leverage to between 2.5x-3.0x, from a previous range of 3.0x-3.5x.
($1 = 0.8650 euros)
(Reporting by Tristan Veyet in Gdansk, Patricia Weiss and Stefanie Geiger in Frankfurt, editing by Matt Scuffham)
Fresenius Medical Care aims to achieve a 'mid-teens' percent operating income margin excluding one-off items by 2030.
Investors were underwhelmed by the targets, leading to a share price drop of as much as 5.6%, making it the poorest performer in Germany's blue-chip index.
The company plans to allocate between 800 million euros to 1 billion euros for capital expenditure each year from 2025 to 2030.
Fresenius Medical Care plans to return excess capital to shareholders through a dividend payout of 30 to 40% along with regular share buybacks.
The company is targeting an additional 300 million euros in savings within the next two years.
Explore more articles in the Finance category
